<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7215134\results\search\drug\results.xml">
  <result pre="Short Report Knowledge-based repositioning of the anti-HCV direct antiviral agent" exact="Sofosbuvir" post="as SARS-CoV-2 treatment http://orcid.org/0000-0002-6380-7114BuonaguroLuigil.buonaguro@istitutotumori.na.it1BuonaguroFranco M.2[1], grid.417893.00000 0001 0807 2568Laboratory"/>
  <result pre="a possible repositioning of the anti-HCV direct antiviral agent (DAA)" exact="Sofosbuvir" post="as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp)"/>
  <result pre="sequence and structural homology, supporting the likelihood of binding the" exact="Sofosbuvir" post="molecule with similar efficiency. Such a repositioning would allow"/>
  <result pre="treatment of the two previous coronavirus epidemics [6]. Similarly, anti-malaria" exact="chloroquine" post="or hydroxychloroquine are tested [7]. The inhibitor of Influenzaâ€™s"/>
  <result pre="the two previous coronavirus epidemics [6]. Similarly, anti-malaria chloroquine or" exact="hydroxychloroquine" post="are tested [7]. The inhibitor of Influenzaâ€™s polymerase Favipiravir"/>
  <result pre="clinical use, is hepatitis C virus (HCV). In the specific," exact="Sofosbuvir" post="(SovaldiÂ®; EpclusaÂ® by Gilead) is a direct antiviral agent"/>
  <result pre="from negative-sense Influenza and Ebola RNA viruses. Therefore, repositioning of" exact="Sofosbuvir" post="(SovaldiÂ®; EpclusaÂ® by Gilead), the inhibitor of the HCV"/>
  <result pre="by the great diversity between the molecular structure of the" exact="Sofosbuvir" post="and the inhibitors of Influenza and Ebola viruses currently"/>
  <result pre="Remdesivir (developed for the Ebola virus) are shown together with" exact="Sofosbuvir" post="(developed for the HCV) Moreover, Sofosbuvir is a prodrug"/>
  <result pre="are shown together with Sofosbuvir (developed for the HCV) Moreover," exact="Sofosbuvir" post="is a prodrug of the protide type and is"/>
  <result pre="comparable to liver cells, ensuring the appropriate activation of the" exact="Sofosbuvir" post="to become an effective substrate of the SARS-CoV-2 RdRp"/>
  <result pre="respiratory tract. In conclusion, the data here reported indicate the" exact="Sofosbuvir" post="as the lead compound with the highest potential of"/>
  <result pre="humans will hold the premises of the in silico analyses," exact="Sofosbuvir" post="will become an extraordinary therapeutic tool to inhibit the"/>
  <result pre="S. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. J Crit Care. 2020;S0883-9441(20)30390â€&quot;7."/>
 </snippets>
</snippetsTree>
